To examine the Framingham Stroke Risk Profile (FSRP); the Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) risk score, and oxiinflammatory load (cumulative risk score of three blood biomarkers-homocysteine, interleukin-6, C-reactive protein) for associations with cognitive decline using three cohort studies of very old adults and to examine whether incorporating these biomarkers with the risk scores can affect the association with cognitive decline. DESIGN: Three longitudinal, population-based cohort studies. SETTING: Newcastle-upon-Tyne, United Kingdom; Leiden, the Netherlands; and Lakes and Bay of Plenty District Health Board areas, New Zealand.
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isk factors for cardiovascular disease (CVD) and stroke, such as hypertension and high cholesterol, have been associated with cognitive decline and dementia. 1 Many cardiovascular risk factors co-occur, and risk From the a prediction models such as the Framingham Stroke Risk Profile (FSRP) 2 have been developed to predict an individual's risk of future CVD or stroke. The Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) risk score was specifically developed for the midlife population to predict future risk of dementia based on cardiovascular and lifestyle factors. 3 Blood biomarkers such as C-reactive protein (CRP), homocysteine, and interleukin (IL)-6 are independent risk factors for CVD. 4 Previous longitudinal studies have suggested a positive association between higher cardiovascular risk and faster rate of cognitive decline, but these studies have been conducted in midlife and younger-old populations; [5] [6] [7] [8] [9] [10] [11] [12] this association has not been explored in very old adults. Cardiovascular biomarkers, such as homocysteine, CRP, and IL-6, have also been associated with cognitive decline, [13] [14] [15] but previous research has not focused on very old adults.
Identifying individuals at the highest risk of dementia is important for developing targeted intervention strategies for the primary prevention of dementia. Determining risk of cognitive decline and dementia in cognitively healthy individuals is difficult because of the numerous risk factors and individual variability in different populations. For example, certain risk factors may affect age groups differently. Nevertheless, several dementia risk prediction models have been proposed and investigated in population-based longitudinal studies, for example the Australian National University-Alzheimer's Disease Risk Index, the CAIDE model, the Brief Dementia Screening Indicator, and the Late-Life Dementia Risk Index, which was developed in an older population (mean age 76), but a recent systematic review concluded that the current models available were not adequate for discriminating individuals who later developed dementia from those who did not. 16 Studying very old adults presents an opportunity to identify factors associated with cognitive impairment at the extreme end of aging that are potential targets for intervention to maintain cognitive performance. Predicting what affects cognitive health may also have implications for prolonging healthy life expectancy. 17 The objectives of this study were to determine whether there was a prospective association between the FSRP, 18 the CAIDE risk model, 3 or oxi-inflammatory load (a sum score of three biomarkers: homocysteine, IL-6, CRP) and cognitive function in very old individuals. Whether combining oxi-inflammatory load with the FSRP and CAIDE risk model could strengthen the association with cognitive function was also examined. Population-based data from three of the largest cohort studies in this age group from different regions of the world were used: Newcastle 85 + Study (United Kingdom), Leiden 85-plus Study (the Netherlands) and Life and Living in Advanced Age: A Cohort Study in New Zealand (LiLACS NZ) Study (non-M aori cohort only).
METHODS
All of the data sets used in this study were from longitudinal population-based studies of health and aging in very old adults.
Newcastle 85+ Study
All adults born in 1921 who were permanently registered with a participating general practice in Newcastle upon Tyne and North Tyneside (northeast England) were invited to participate. 19, 20 A trained research nurse administered a multidimensional health assessment in the participant's usual place of residence. Of 1,453 eligible people invited to participate, 845 had baseline data for the detailed multidimensional health assessment and general practice record review. Those with a history of stroke or dementia were excluded from all analyses, in line with previous studies examining associations between the Framingham Stroke Risk Profile and cognitive function. [21] [22] [23] Six hundred sixteen participants had complete clinical and laboratory data and no previous history of stroke or dementia at baseline. Follow-up assessments took place 18, 36, and 60 months from baseline. 24 
Leiden 85-plus Study
Of the 705 residents of Leiden who turned 85 between September 1, 1997, and September 1, 1999, and were eligible to participate, 599 responded and participated in the study. 25 At baseline, 444 participants had complete clinical and laboratory data and no previous history of stroke or dementia and were included in this analysis. Participants were visited at their usual place of residence for a detailed health assessment, and their medical records from their primary care physician were also reviewed. There were five annual follow-up assessments.
LiLACS NZ Study
The cohort was derived from two separate populations comprising M aori (indigenous people in New Zealand) and non-M aori. 26 The current study included only the non-M aori cohort aged 85 years old at baseline to allow comparison with the other included cohorts. Individuals born between January 1 and December 31, 1925, who resided within the Lakes or Bay of Plenty District Health Board areas when study enrollment was completed in 2010 were recruited. Of the 870 eligible non-M aori individuals, 516 enrolled in the study. 27 At baseline, 396 who had complete clinical and laboratory data and no previous history of stroke or dementia were included in this analysis. Participants were given the choice to meet at their usual place of residence or at another site to complete a structured face-to-face standardized questionnaire and a detailed health assessment; general practice medical records were reviewed. This analysis included data from three annual follow-up assessments.
Assessment of the Risk Prediction Models
The FSRP and the CAIDE models were determined in each study using baseline data. Table S1 presents the variables included in each model and their measurements. All variables, with the exception of education and physical activity, were measured similarly across the cohorts.
Information on apolipoprotein E4 was not available for the LiLACS NZ data set. For analysis, FSRP and CAIDE scores were divided into study-specific tertiles to create low-, intermediate-, and high-risk groups, with the lowrisk group used as the reference category.
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Biomarkers and Oxi-Inflammatory Load Three biomarkers previously shown to be associated with CVD were selected from the blood results, including two inflammatory biomarkers (CRP, IL-6) and one biomarker for oxidative stress (homocysteine). 4 Details of the biomarker assays in each study can be found in the Appendix S1. The distributions of the biomarkers were skewed, so the data were log transformed. A fixed value of 0.1 was added to each data point, including 0 values, to calculate the logarithmic value. To determine the combined effect of all three biomarkers, a cumulative score of the standardized z-scores for each log-transformed biomarker value was created and is referred to as a participant's oxi-inflammatory load. Homocysteine was not available for the LiLACS NZ data set, so the cumulative score could not be calculated in this cohort.
As in previous analyses, biomarkers and oxi-inflammatory load scores were grouped into deciles, and participants were allocated to one of three groups (<10th percentile, 10th-90th percentile, >90th percentile), with the middle category being used as the reference. 29 A sensitivity analysis grouping oxi-inflammatory load scores into three tertiles (with the middle category used as the reference) was also conducted.
To examine whether oxi-inflammatory load scores could improve prediction of cognitive impairment using the FSRP or the CAIDE model, analyses were repeated after adding points to the CAIDE and FSRP scores based on oxi-inflammatory load values of participants; specifically, six points were added for the highest tertile of oxiinflammatory load, three points for the middle tertile, and no points for the lowest tertile.
Cognitive Assessment
Global cognitive function was assessed in all three cohorts using the standard Mini-Mental State Examination (MMSE; range 0-30). 30 The MMSE was conducted at baseline, 36 months, and 60 months in the Newcastle 85+ Study; at baseline and annually for 5 years in the Leiden 85-plus Study; and at baseline and annually for 3 years in the LiLACS NZ Study. Cognitive impairment at baseline and incident cognitive impairment at each follow-up was defined as a score of 25 points or less.
Domain-specific cognitive functions including attention, information processing, and episodic verbal recognition memory were assessed in the Newcastle 85+ Study using the Cognitive Drug Research (CDR) System. Details of the cognitive assessments in the Newcastle 85+ Study have been published elsewhere. 31 The CDR System was conducted at baseline, 18, and 36 months.
In the Leiden 85-plus Study, speed of information processing was measured using the Letter Digit Coding Test. Attention was measured using the Stroop Test Part 3. Memory was measured using the 12-word learning test.
These tests were administered at baseline and annually for 5 years. There were no domain-specific tests administered in the LiLACS NZ Study.
Statistical Analysis
Cox proportional hazards models were run to determine whether FSRP and CAIDE scores and oxi-inflammatory load were associated with impairments in global or domain-specific cognitive function (dichotomized variables) over the follow-up period in each study. Tests of the proportional hazards assumption were run for each model and were not violated. Biomarker models were adjusted for potential confounding factors including sex, years of education, current alcohol consumption, and smoking status.
Following this, a Meta-analysis of the highest HR category was conducted to estimate the pooled effects of the FSRP, CAIDE, and oxi-inflammatory load scores on prospective risk of impaired global cognitive function (MMSE scores). HRs and 95% confidence intervals (CIs) for each study were entered into the models. Statistical heterogeneity was assessed using the I 2 and the Q tests, and P < .10 was chosen as a cut-off for heterogeneity.
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A fixed-effect model was applied because of the lack of heterogeneity (Q test, P > .10), and forest plots were generated for the FSRP, CAIDE, and oxi-inflammatory load scores. Comprehensive Meta-Analysis 2 software (Biostat, Engelwood, NJ) was used to conduct the analysis.
Linear mixed models were used to examine change in continuous test scores for each cognitive measure. Cognitive test scores that were positively skewed (power of attention, simple reaction time, Stroop Test Part 3) were logarithmically transformed, and MMSE scores (which were negatively skewed) were corrected using the formula ffiffi ð p K À xÞ where K is the maximum score, and x is the participant's score. Each model included the risk model or biomarker score (cross-sectional effect), time (change in cognitive scores over time), and an interaction term between the risk model or biomarker score and time (additional effect of the risk model or biomarker score). All data were analyzed using Stata version 13.0 (Stata Corp., College Station, TX).
RESULTS
After excluding participants with a history of stroke or dementia at baseline, the analytical sample included 616 participants in the Newcastle 85 + Study, 444 in the Leiden 85-plus Study, and 396 in the LiLACS NZ Study. The baseline characteristics of each sample are shown in Table 1 .
Framingham Stroke Risk Profile

Global Cognitive Function
For the individual studies, the HRs for greater risk of impaired global cognitive function were all greater than 1 for the highest FSRP groups ( cognitive function with a higher FSRP (MMSE: HR = 1.46, 95% CI = 1.08-1.98, P = .01), although in the linear mixed models, none of the associations between the FSRP and global cognitive function (cross-sectional results) or global cognitive decline were significant (P > .05, Table 3 ).
Domain-Specific Cognitive Function
Upon examining the specific cognitive domains, which were available only for the Newcastle 85+ and Leiden 85-plus studies, higher FSRP scores were associated with greater risk of impaired speed of reaction times for the Newcastle 85+ Study (HR = 1.42, 95% CI = 1.06-1.91, P = .02) (Table S2 ). In the linear mixed models, the FSRP was cross-sectionally associated with speed scores for the Leiden 85-plus Study only (Letter Digit Coding Test: (Β = À2.19 (standard error (SE) 0.913), P = .02) ( Table S3 ).
The CAIDE Model
Global Cognitive Function
Higher CAIDE scores were associated with an increased risk of impaired global cognitive function in the meta-analysis of pooled MMSE results (HR = 1.53, 95% CI = 1.09 to 2.14, P = .01). The Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) score for LiLACS NZ does not include apolipoprotein E4; the oxi-inflammatory load for the study is based only on interleukin-6 and C-reactive protein. Education for the Leiden 85-plus Study is based not on years of education but is determined according to the categorizations of education used in that study. In the Newcastle 85+ Study, memory was measured using the sensitivity index for recognition ability, attention was measured using power of attention, and speed was measured using simple reaction time-all part of the Cognitive Drug Research computerized assessment system. In the Leiden 85-plus Study, memory was measured using the Word-Learning Test, Immediate and Delayed Recall (based on sum of z scores); attention was measured using the Stroop Test Part 3; and speed was measured using the Letter Digit Coding Test. Numbers exclude people with dementia or stroke at baseline. IQR = interquartile range; SD = standard deviation.
Domain-Specific Cognitive Function
The CAIDE model was not longitudinally associated with any of the domain specific cognitive test scores for the Newcastle 85+ or Leiden 85-plus studies for either the Cox proportional hazard models or the linear mixed models. However, the linear mixed models showed that the CAIDE model was cross-sectionally associated with speed, attention and memory scores for the Leiden 85-plus Study.
Oxi-Inflammatory Load
Global Cognitive Function
Higher oxi-inflammatory load was associated with incident global cognitive impairment in the meta-analysis of pooled results (Newcastle 85+ Study and Leiden 85-plus Study only: HR = 1.73, 95% CI = 1.04-2.88, P = .04) (Figure 1) . In linear mixed models, oxi-inflammatory load was not longitudinally associated with global cognitive decline, but a cross-sectional association was observed between higher oxi-inflammatory load and poorer global cognitive function scores at baseline (Β = 0.320 (SE 0.127), P = .01) in the Leiden 85-plus Study.
Domain-Specific Cognitive Function
Higher oxi-inflammatory load was associated with greater risk of incident impairment of attention in the Newcastle 85+ Study (HR = 1.58, 95% CI = 1.05-2.36, P = .03) and Leiden 85-plus Study (HR = 2.18, 95% CI = 1.27-3.74, P = .01) (Table S2 ). Higher oxi-inflammatory load was also associated with greater risk of impairment of speed in the Newcastle 85+ Study (HR = 1.85, 95% CI = 1.24-2.75, P = .003), but this association was not observed in the Leiden 85-plus Study. In the linear mixed models, higher oxi-inflammatory load was not longitudinally associated with any of the domain-specific cognitive test results for the Newcastle 85+ or Leiden 85-plus studies, although the linear mixed models showed that higher oxi-inflammatory load was cross-sectionally associated with better attention scores for the Newcastle 85+ Study (Β = 0.058 (SE 0.028), P = .04) (Table S3) .
Adding Oxi-Inflammatory Load to the FSRP and CAIDE Model
To determine whether oxi-inflammatory load could be used to improve prediction of the FSRP or CAIDE models, oxi-inflammatory load scores were added to FSRP and CAIDE scores, as described in Methods. In the metaanalysis of pooled results (Newcastle 85+ Study and Leiden 85+ Study only), adding oxi-inflammatory load scores improved the prediction of the CAIDE (HR = 1.93, 95% CI = 1.39-2.67, P < .001) and FSRP scores (HR = 1.65, 95% CI = 1.17-2.33, P < .001).
Sensitivity Analysis
The Leiden 85-plus data set did not include years of education and instead used a measure based on the education system in the Netherlands. Therefore, the analysis of the CAIDE score was repeated with education excluded from the calculation to determine whether differences in the operationalization of education were the reason for the discrepant results between the studies. When education was excluded, the result changed, and the CAIDE score 
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Global cognitive function measured using the Mini-Mental State Examination (MMSE) in all studies. Oxi-inflammatory load is a sum score of the three biomarkers; standardized z-scores for each log-transformed biomarker were calculated, and the sums of these scores were determined to characterize oxiinflammatory load. Categories were based on tertiles for the FSRP and CAIDE models and for oxi-inflammatory load: low is <10th percentile, middle is 10th-90th percentile, and high is >90th percentile. Impairment is ≤25 points on the MMSE for global cognitive function. Oxi-inflammatory load models adjusted for sex, years of education, current alcohol consumption, and smoking status. Global cognitive function was measured using the Mini-Mental State Examination (MMSE) in all studies. Cognitive tests that were not normally distributed were transformed. Oxi-inflammatory load is a sum score of the three biomarkers; standardized z-scores for each log-transformed biomarker were calculated, and the sums of these scores were determined to characterize oxi-inflammatory load. Categories were based on tertiles for the FSRP and CAIDE models and for oxi-inflammatory load: low is <10th percentile, middle is 10th-90th percentile, and high is >90th percentile. For the non-MMSE measurements, impairment was defined as a score 1.5 standard deviations or more below (or above where higher scores indicate worse performance) the mean score. If scores were not normally distributed, this was calculated as the 93rd percentile for scores for which higher numbers reflect worse cognitive function and the 7th percentile for scores for which lower numbers reflect worse cognitive function. Oxi-inflammatory load models adjusted for sex, years of education, current alcohol consumption, and smoking status.
was no longer associated with global cognitive impairment (Leiden 85-plus: highest-vs lowest-risk tertile: HR = 1.25, 95% CI = 0.81-1.92, P = .30). Analyses for the Cox proportional hazards models were repeated using tertiles for oxi-inflammatory load (middle category as reference) (MMSE: HR = 1.36, 95% CI = 0.96-1.92, P = .07).
DISCUSSION
Three prospective studies of 85-year-old individuals free of stroke or dementia at baseline from the United Kingdom, the Netherlands, and New Zealand found that higher FSRP and CAIDE risk scores and higher oxi-inflammatory load derived from a cumulative score of three cardiovascular biomarkers were associated with incident global impairment. Furthermore, incorporating oxi-inflammatory load scores into the FSRP or CAIDE model improved the ability of the risk models to predict incident global cognitive impairment, although this could only be determined using two of the three studies (Newcastle 85+ Study, Leiden 85-plus Study) because the LiLACS NZ Study did not have the homocysteine measures needed to determine oxiinflammatory load.
Several longitudinal studies have found a positive association between higher scores from the Framingham and CAIDE risk models and greater risk of cognitive decline or dementia (for a review of studies see 21 ), but when investigating specific cognitive domains, the results have been inconsistent with regard to which cognitive domains higher cardiovascular risk may affect. [5] [6] [7] [8] 11, 33 Furthermore, the majority of studies have focused on midlife and younger old populations, and no study has previously examined the association between cardiovascular risk models and cognitive function in very old adults.
Studies in younger populations have found that homocysteine, IL-6, and CRP predict cognitive decline. [13] [14] [15] Previous findings in the Newcastle 85 + Study have found cross-sectional associations between these biomarkers and global cognitive impairment measured using the MMSE. 29 Similarly, previous findings in the Leiden 85-plus Study have found cross-sectional associations between homocysteine and cognitive impairment, but this association was not found with rate of cognitive decline. 34 In the current study, higher levels of biomarkers for oxidative stress and inflammation were longitudinally associated with greater risk of developing global and domainspecific cognitive (speed and attention) impairment. Biomarkers of cardiovascular risk may be useful for identifying individuals at risk of future cognitive impairment, because oxidative stress and inflammation are implicated in the pathophysiology of dementia. Higher levels of oxidative stress, impaired cellular function linked to abnormal protein accumulation, and modification of molecular structures may have direct effects on neuronal structure and integrity, affecting cognitive function. 35 Furthermore, inflammation is thought to be important in neurodegeneration, contributing to the development of some of the classic hallmarks of Alzheimer's pathology such as amyloid-beta plaques. 36 These findings have been formalized in the theory of inflammaging as a critical factor in the pathogenesis of age-related chronic cardiovascular and neurodegenerative diseases. 37, 38 Current dementia risk prediction models are not sufficient to detect those at greatest risk of developing cognitive impairment or dementia. 16 Factors incorporated into current dementia risk prediction models include demographic factors (e.g., age, sex, ethnicity), subjective cognitive complaints, functioning (as measured using activity of daily living scales), neuropsychological test scores, healthrelated measures (e.g., history of CVD, body mass index), lifestyle measures (e.g., smoking status, alcohol intake), dietary factors (e.g., folic acid and fish intake), magnetic resonance imaging results (e.g., white matter disease), and others (e.g., family history of dementia). The best models were described as those that incorporated a diverse range of risk factors, but it is most likely that there will not be one model that is suitable for all populations, and different dementia risk models may need to be developed for different age groups. 39 No such dementia risk model has been validated in a very old population. The development of a highly accurate model for discriminating those at high risk of future dementia from those at medium and low risk would be required before screening the older population for future risk of dementia in primary care practice could become a possibility. Incorporation of the biomarkers investigated in this study into the classical cardiovascular risk factors of the FSRP or CAIDE models may be useful to investigate when developing a dementia risk prediction model for very old adults.
There are strengths and limitations to this study. The Newcastle 85+, Leiden 85-plus, and LiLACS NZ cohorts are prospective longitudinal cohort studies of very old adults, and this is the first study that has aggregated data from all three cohorts.
There are some limitations. The LiLACS NZ Study did not have homocysteine levels needed to determine oxiinflammatory load, so findings for oxi-inflammatory load are based on the Newcastle 85+ and Leiden 85-plus studies only.
Results were not always consistent across the studies; these discrepancies may be due to differences in the assays used to determine CRP and IL-6 between the two studies, because the Leiden 85-plus Study used less-sensitive assays, which led to the attribution of values of 0 for results lower than the limit of detection (number of 0 values: CRP = 82, IL-6 = 119); differences in the cohorts themselves (e.g., education levels; the Leiden 85+ Study did not have years of education, which was needed to calculate CAIDE scores, the LiLACS Study did not have the apolipoprotein E4 measurement, which was required for the CAIDE model); differences in the cognitive tests used to assess domain-specific cognitive function; the smaller sample size of the Leiden 85-plus and LiLACS NZ studies; or a cohort effect related to differences in birth year between cohorts (1913-1915 (Leiden 85-plus Study), 1921 (Newcastle 85+ Study), 1925 (LiLACS NZ Study)).
Further research in very old adults is needed to gain a full understanding of the association between the Framingham models, the CAIDE models, or cardiovascular biomarkers and cognitive decline, in particular with respect to which cognitive domains may be most likely to be affected.
There is no recommended tool for identifying very old individuals at risk of developing cognitive impairment or dementia. 16 Combining oxi-inflammatory load with the FSRP or the CAIDE model may improve the ability of these models to predict cognitive changes. Biomarkers would be relatively easy to measure in a clinical setting and could potentially provide clinicians with an overview of an individual's cardiovascular health in addition to their future risk of cognitive impairment. Intervention strategies to reduce oxi-inflammatory load could potentially target improvements in cardiovascular health and cognitive function.
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